8-K: Avalon GloboCare Corp. Secures $400K Via Preferred Stock Sale

Avalon GloboCare Corp. announced a $400,000 financing through the sale of Series F Convertible Preferred Stock and common stock to an accredited investor.

Summary

• Avalon GloboCare Corp. entered into a securities purchase agreement on June 30, 2026, with an accredited investor, Allen O. Cage Jr.
• The company agreed to issue 400 shares of Series F Convertible Preferred Stock and 200,000 shares of common stock for an aggregate purchase price of $400,000.
• The Series F Preferred Stock is convertible into common stock at $0.50 per share, subject to a 4.99% beneficial ownership limitation.
• The transaction closed on July 2, 2026.
• The Series F Preferred Stock has a stated value of $1,000 per share and ranks senior to common stock but junior to other preferred stock in liquidation preference.
• Mandatory redemption of 25% of outstanding Series F Preferred Stock will occur on October 1, 2026, November 1, 2026, December 1, 2026, and January 1, 2027, at 125% of the stated value, unless converted.
• The company also issued options to purchase 1,150,000 shares of common stock to officers and 600,000 shares to non-employee directors on June 29, 2026, with an exercise price of $0.2820 per share.
• Additional shares of common stock were issued to consultants on June 29, 2026, and July 2, 2026, for services rendered.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral financing event; while it provides capital, the convertible nature and mandatory redemption introduce potential future dilution and financial obligations.

Positives

• Secured $400,000 in funding through a private placement.
• The convertible preferred stock offers a conversion price of $0.50 per share, potentially benefiting from future stock price appreciation.
• Issuance of stock options to officers and directors aligns incentives and compensates for services.
• The company is actively managing its capital structure through preferred stock issuances and option grants.

Negatives

• The company is issuing convertible preferred stock, which can lead to dilution for common stockholders upon conversion.
• Mandatory redemption at a premium (125% of stated value) represents a future cash outflow or further dilution if converted.
• The conversion price of $0.50 per share is significantly higher than the exercise price of options granted to officers and directors ($0.2820), suggesting a higher valuation expectation for the preferred stock investors.
• The need for shareholder approval for conversion implies potential concerns about dilutive effects.

Risks

• Potential for significant dilution to existing common stockholders if the Series F Preferred Stock is converted.
• The mandatory redemption feature at a premium could strain cash resources or lead to further equity issuance.
• The 4.99% beneficial ownership limitation on conversion may restrict the ability of investors to fully convert their holdings.
• The company's reliance on private placements for capital may indicate challenges in accessing traditional financing or public markets.
• The need for shareholder approval for conversion could introduce uncertainty if approval is not obtained.

Future Outlook

The company is subject to mandatory redemption of its Series F Convertible Preferred Stock on specified dates in late 2026 and early 2027, with options for holders to convert prior to redemption. The conversion of Series F Preferred Stock into common stock is contingent upon obtaining shareholder approval.

Industry Context

StockSavvy.ai notes that Avalon GloboCare Corp.'s financing strategy, involving convertible preferred stock and stock options, is common for biotechnology and healthcare companies seeking capital for development and operations, especially when facing market volatility or seeking to avoid immediate dilution from traditional equity offerings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution upon conversion of Series F Preferred Stock; mandatory redemption may lead to cash outflow or further dilution.
• Management and Employees: Granted stock options, aligning incentives with company performance.
• Creditors: Mandatory redemption could impact cash availability for debt servicing if not managed effectively.

Next Steps

• Obtain shareholder approval for the conversion of Series F Convertible Preferred Stock.
• Manage mandatory redemption obligations for Series F Convertible Preferred Stock on October 1, 2026, November 1, 2026, December 1, 2026, and January 1, 2027.
• Continue efforts to maintain the listing of Common Stock on Nasdaq.

Key Dates

Recommendation

The financing provides necessary capital but introduces potential dilution and future financial obligations. The company's ability to secure shareholder approval for conversions and manage redemptions will be key factors. Investors should monitor these developments.

Keywords

Avalon GloboCare Corp., Form 8-K, Securities Purchase Agreement, Series F Convertible Preferred Stock, Private Placement, Financing, Common Stock, Stock Options